Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunologic approaches to acute leukemia in the elderly.

Sherif S Farag1, Michael A Caligiuri

  • 1Division of Hematology and Oncology, Department of Internal Medicine and The Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA. sherif.farag@osumc.edu

Seminars in Hematology
|April 18, 2006
PubMed
Summary

Older patients with acute leukemia have poor outcomes. Novel natural killer (NK) cell therapies show promise by targeting leukemia cells, offering new hope for improved survival in elderly patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First-in-human study of FLT3 CAR-T cell therapy for relapsed acute myeloid leukemia.

NPJ precision oncology·2026
Same author

Epigenetic activation of EBV BGLF4 determines antiviral-based regimen response in EBV+CNS lymphoproliferative disease.

Blood neoplasia·2026
Same author

Human type-1 innate lymphoid cells control leukemia stem cell differentiation and limit acute myeloid leukemia development.

Nature communications·2026
Same author

Human pluripotent stem cell-derived innate and adaptive immune cells for cancer immunotherapy.

Cell stem cell·2026
Same author

Optimizing In Vivo CAR T-cell Engineering for Cancer Immunotherapy.

Cancer research·2026
Same author

No BCMA? No Problem: A CD70-Targeting CAR-NK Cell Shows Promise in High-risk Myeloma.

Blood cancer discovery·2025

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • Acute leukemia outcomes in older adults are poor, necessitating treatments independent of chemotherapy resistance.
  • Natural killer (NK) cells offer potential for cancer immunotherapy due to their ability to target tumor cells without specific antigen recognition.
  • Current NK cell therapies for acute leukemia, primarily in vivo expansion and cytokine activation, have shown limited success.

Purpose of the Study:

  • To review the biological basis for using NK cells in cancer immunotherapy.
  • To explore novel therapeutic strategies for leveraging NK cell functions in elderly acute leukemia patients.
  • To highlight future directions for NK cell-based treatments in this demographic.

Main Methods:

  • Review of existing literature on NK cell biology and function in cancer.

Related Experiment Videos

  • Analysis of NK cell receptor interactions with target cells, including MHC class I molecules.
  • Discussion of recent advancements and emerging therapeutic approaches.

    • Main Results:

    • NK cell activity is regulated by a balance of activating and inhibitory signals through surface receptors.
    • Understanding these receptor-ligand interactions is key to developing targeted NK cell therapies.
    • Novel strategies focus on enhancing NK cell recognition and cytotoxic function against leukemia cells.

    Conclusions:

    • NK cell-based immunotherapy presents a promising avenue for treating acute leukemia, particularly in older patients.
    • Harnessing NK cell receptor pathways offers a strategy to overcome chemotherapy resistance.
    • Future research should focus on optimizing NK cell therapies for improved patient outcomes in elderly acute leukemia.